Abstract:The consequences of cannabis use, especially in the context of schizophrenia, have gained increased importance with the legalization of cannabis in North America and across the globe. Cannabis use has multifaceted impacts on cognition in schizophrenia patients and healthy subjects. Healthy subjects, particularly those who initiated cannabis use at earlier ages and used high-potency cannabis for longer durations, exhibited poorer cognition mainly in working memory and attention. Cannabis use in schizophrenia has been associated with symptom exacerbation, longer and more frequent psychotic episodes, and poorer treatment outcomes. However, cannabis-using patients have better overall cognitive performance compared to patients who were not cannabis users. Interestingly, these effects were only apparent in lifetime cannabis users, but not in current (or within last 6 months) users. Moreover, higher frequency and earlier age of cannabis use initiation (i.e., before 17 years of age) were associated with better cognitive performance, although they had an earlier illness onset. Three possible hypotheses seem to come forward to explain this paradox. First, some components of cannabis may have antipsychotic or cognitive-enhancing properties. Secondly, chronic cannabis use may alter endocannabinoid signaling in the brain which could be a protective factor for developing psychosis or cognitive impairments. A third explanation could be their representation of a phenotypically distinct patient group with more intact cognitive functioning and less neurodevelopmental pathology. Multiple factors need to be considered to understand the complex relationship between cannabis, cognitive function, and schizophrenia. In short, age at initiation, duration and rate of cannabis use, abstinence duration, co-use of substances and alcohol, prescribed medications, relative cannabinoid composition and potency of cannabis, presence of genetic and environmental vulnerability factors are prominent contributors to the variability in outcomes. Animal studies support the disruptive effects of Δ9-tetrahydrocannabinol (THC) administration during adolescence on attention and memory performance. They provide insights about interaction of cannabinoid receptors with other neurotransmitter systems, such as GABA and glutamate, and other regulatory molecules, such as PSD95 and synaptophysin. Cannabidiol (CBD), on the other hand, can improve cognitive deficits seen in neurodevelopmental and chemically-induced animal models of schizophrenia. Future studies focusing on bridging the translational gaps between human and animal studies, through the use of translationally relevant methods of exposure (e.g., vaping), consistent behavioral assessments, and congruent circuit interrogations (e.g., imaging) will help to further clarify this complex picture.

Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis

Adolescent exposure to Δ 9 -tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons

Intoxication due to Δ9-tetrahydrocannabinol is characterized by disrupted prefrontal cortex activity

P.1.e.014 The acute effects of delta-9-tetrahydro-cannabinol (THC) on brain activity during working memory

Acute Effects of ∆9-Tetrahydrocannabinol (THC) on Resting State Brain Function and Their Modulation by COMT Genotype.

Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity

Evidence for Involvement of the Insula in the Psychotropic Effects of THC in Humans: a Double-Blind, Randomized Pharmacological MRI Study.

The Relationship Between Cannabis, Cognition, and Schizophrenia: It's Complicated

P.1.e.005 Delta9-tetrahydrocannabinol (THC) impairs working memory system capacity: a pharmacological MRI study

Impaired Cognitive Performance under Psychosocial Stress in Cannabis-Dependent Men is Associated with Attenuated Precuneus Activity

Chronic exposure to inhaled vaporized cannabis high in THC suppresses Adderall-induced brain activity

Cognitive Function in Individuals with Psychosis: Moderation by Adolescent Cannabis Use.

Delta 9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum

Altered fronto-occipital connectivity during visual selective attention in regular cannabis users

Impaired cognitive performance under psycho-social stress in cannabis-dependent males is mediated by attenuated precuneus activity

Effects of Δ9-Tetrahydrocannabinol Administration on Human Encoding and Recall Memory Function: A Pharmacological Fmri Study

Alterations in self-reported sensory gating and interoception in individuals frequently using cannabis

Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users.

Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects

Detrimental effects of adolescent escalating low-dose Δ9 -tetrahydrocannabinol leads to a specific bio-behavioural profile in adult male rats

Central Nervous System Effects of Haloperidol on THC in Healthy Male Volunteers.